Treace to Present at Truist Securities MedTech Conference
Treace Medical Concepts announced its participation in the Truist Securities MedTech Conference on June 18, 2024, at 8:00 am Eastern Time. CEO John T. Treace and CFO Mark L. Hair will join a fireside chat during the event. The discussion will be webcasted live and available for replay on Treace's investor relations website. Treace, known for its Lapiplasty® and Adductoplasty® Procedures, spearheads advancements in the surgical treatment of bunions and midfoot deformities.
- Participation in a prominent MedTech conference can increase company visibility.
- Live webcast and replay availability can reach a broader investor audience.
- Showcase of flagship procedures like Lapiplasty® and Adductoplasty® could attract investor interest.
- No new product announcements or financial updates provided.
- Absence of concrete data or metrics on company performance in the announcement.
Tuesday, June 18, 2024 at 8:00 am Eastern Time
PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:00 am Eastern Time.
A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Julie Dewey, IRC
Chief Communications & Investor Relations Officer
jddewey@treace.com | 209-613-6945
FAQ
When is Treace presenting at the Truist Securities MedTech Conference?
What company will join the Truist Securities MedTech Conference?
Who will represent Treace at the Truist Securities MedTech Conference?
Where can I watch the Treace presentation at the Truist Securities MedTech Conference?
What procedures will Treace discuss at the conference?
